



ACERUS PROVIDES UPDATE ON LITIGATION

Toronto, Canada, May 17, 2016 – Acerus Pharmaceuticals Corporation (TSX:ASP) today served a notice of motion to strike the statement of claim filed in the Ontario Superior Court of Justice by Mr. Eugene Melnyk against the company, as well as its Chairman and President & Chief Executive Officer.

Acerus is proceeding with a motion to strike on the grounds that the claim discloses no reasonable cause of action and that the claim is frivolous, scandalous and/or vexatious, and represents an abuse of process of the court. The company maintains its position regarding the appropriate conduct of the business and its management, and will continue to vigorously defend against all such claims that imply otherwise.

About Acerus

Acerus Pharmaceuticals Corporation is a Canadian pharmaceutical company focused on the development, manufacture, marketing and distribution of innovative, branded products that improve the patient experience.

Acerus markets ESTRACE® in Canada, a product indicated for the symptomatic relief of menopausal symptoms. NATESTO™, a product utilizing an Acerus licensed nasal gel technology, is the first and only testosterone nasal gel approved in Canada, and available in the United States for replacement therapy in adult males diagnosed with hypogonadism. GYNOFLOR™, a product licensed to Acerus in Canada by Medinova AG and approved in 39 countries worldwide, is an ultra-low dose vaginal estrogen therapy with the addition of lactobacillus, for the treatment of atrophic vaginitis, certain vaginal infections and/or to restore a healthy vaginal environment. TEFINA™, a 'use as required' nasal testosterone gel, is an Acerus drug development candidate aimed at addressing a significant unmet need for women with female sexual dysfunction.

For more information, visit www.aceruspharma.com and follow us on [Twitter](#) and [LinkedIn](#).

Notice Regarding Forward-Looking Statements

Information in this press release that is not current or historical factual information may constitute forward looking information within the meaning of securities laws. Implicit in this information are assumptions regarding our future operational results. These assumptions, although considered reasonable by the company at the time of preparation, may prove to be incorrect. Readers are cautioned that actual performance of the company is subject to a number of risks and uncertainties, and could differ materially from what is currently expected as set out above. For more exhaustive information on these risks and uncertainties you should refer to our annual information form dated March 1, 2016 which is available at www.sedar.com. Forward-looking information contained in this press release is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date.

You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time, whether as a result of new information, future events or otherwise, except as required by applicable securities law.

#

Contact

Tiana DiMichele
Director, Marketing & Communications
Acerus Pharmaceuticals Corporation
tdimichele@aceruspharma.com
(416) 679-0822